MindMed reports $273.7M cash, advances MM120 Phase 3 trials in GAD and MDD

Definium Therapeutics, Inc.

Cash and equivalents $273.7M at Dec 31, 2024 vs $99.7M a year ago; raised ~$250M in 2024.
Q4 2024 R&D expense $21.8M (from $11.5M); full-year $65.3M (from $52.1M).
Phase 3 Voyage (GAD) dosing initiated; topline data expected 1H 2026.
Phase 3 Panorama (GAD) initiated Q1 2025; data expected 2H 2026.
On track to start Phase 3 Emerge (MDD) 1H 2025; topline data 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.